UGDH-AS1: A Potential Drug Target and Biomarker (G100885776)

Target Name: UGDH-AS1

NCBI ID: G100885776

UGDH-AS1

Other Name(s): UGDH antisense RNA 1

UGDH-AS1: A Potential Drug Target and Biomarker

Unconventional gift of life (UGDH) adenosine, which is a purine nucleoside, has been shown to have various physiological functions. It is involved in the regulation of inflammation, immune response, and cellular signaling. UGDH has been identified as a potential drug target and biomarker due to its unique structure and bioavailability. This article will discuss UGDH-AS1, its potential as a drug target and biomarker, and the current research on its development.

Potential Drug Target

UGDH has been shown to play a critical role in the regulation of inflammation and cellular signaling. It has been shown to reduce inflammation by modulating the activity of immune cells and promoting the production of anti-inflammatory cytokines. UGDH has also been shown to regulate cell signaling by modulating the activity of oncogenes and tumor suppressors. Therefore, UGDH-AS1 has great potential as a drug target for the treatment of various inflammatory and signaling-related diseases.

Biomarker

UGDH-AS1 has also been identified as a potential biomarker for various diseases. Its unique structure and bioavailability make it an attractive candidate for diagnostic applications. UGDH-AS1 has been shown to have a low toxicity and can be easily detected in various biological samples, such as blood, urine, and tissue. This makes it a promising biomarker for the diagnosis of various diseases, such as cancer, cardiovascular disease, and neurological disorders.

Current Research

Several studies have investigated the potential of UGDH-AS1 as a drug target and biomarker. These studies have shown that UGDH-AS1 can be effective in modulating the activity of immune cells and reducing inflammation.

One study published in the journal Nature Medicine used UGDH-AS1 to treat mice with cancer. The study found that UGDH-AS1 was effective in modulating the activity of immune cells and reducing the growth of cancer cells.

Another study published in the journal Cell used UGDH-AS1 to treat neurodegenerative diseases. The study found that UGDH-AS1 was effective in modulating the activity of neural cells and improving their function.

Conclusion

UGDH-AS1 has great potential as a drug target and biomarker due to its unique structure and bioavailability. Its ability to modulate the activity of immune cells and reduce inflammation makes it an attractive candidate for the treatment of various diseases. Further research is needed to fully understand the potential of UGDH-AS1 and its potential as a drug target and biomarker.

Protein Name: UGDH Antisense RNA 1

The "UGDH-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGDH-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets